Contraception
Volume 78, Issue 4, Supplement , Pages S23-S27 , October 2008

Male contraception: what is on the horizon?

  • Diana Blithe

      Affiliations

    • Corresponding Author InformationTel.: +1 301 435 6990; fax: +1 301 480 1972.

Received 20 March 2008 ,Accepted 20 March 2008.

References 

  1. WHO , UNICEF , UNFPA , The World Bank . Maternal mortality in 2005. Geneva, Switzerland: World Health Organization; 2007;
  2. Trussell J, Wynn LL. Reducing unintended pregnancy in the United States. Contraception. 2008;77:1–5
  3. Heinemann K, Saad F, Wiesemes M, White S, Heinemann L. Attitudes toward male fertility control: results of a multinational survey on four continents. Hum Reprod. 2005;20:549–556
  4. In:  Nass SJ,  Strauss JF editor. New frontiers in contraceptive research: a blueprint for action. Washington, DC: The National Academies Press; 2004;
  5. Handelsman DJ. Update in andrology. J Clin Endocrinol Metab. 2007;92:4505–4511
  6. Wu FC. Hormonal approaches to male contraception: approaching reality. Mol Cell Endocrinol. 2006;250:2–7
  7. Wenk M, Nieschlag E. Male contraception: a realistic option?. Eur J Contracept Reprod Health Care. 2006;11:69–80
  8. Matthiesson KL, McLachlan RI. Male hormonal contraception: concept proven, product in sight?. Hum Reprod Update. 2006;12:463–482
  9. Coviello AD, Bremner WJ, Matsumoto AM, et al. Intratesticular testosterone concentrations comparable with serum levels are not sufficient to maintain normal sperm production in men receiving a hormonal contraceptive regimen. J Androl. 2004;25:931–938
  10. Herbst KL, Coviello AD, Page S, Amory JK, Anawalt BD, Bremner WJ. A single dose of the potent gonadotropin-releasing hormone antagonist acyline suppresses gonadotropins and testosterone for 2 weeks in healthy young men. J Clin Endocrinol Metab. 2004;89:5959–5965
  11. Meriggiola MC, Costantino A, Saad F, et al. Norethisterone enanthate plus testosterone undecanoate for male contraception: effects of various injection intervals on spermatogenesis, reproductive hormones, testis, and prostate. J Clin Endocrinol Metab. 2005;90:2005–2014
  12. Gao W, Dalton JT. Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs). Drug Discov Today. 2007;12:241–248
  13. Attardi BJ, Hild SA, Reel JR. Dimethandrolone undecanoate: a new potent orally active androgen with progestational activity. Endocrinology. 2006;147:3016–3026
  14. Anderson RA, Wallace AM, Sattar N, Kumar N, Sundaram K. Evidence for tissue selectivity of the synthetic androgen 7-alpha-methyl-19-nortestosterone in hypogonadal men. J Clin Endocrinol Metab. 2003;88:2784–2793
  15. Wolgemuth DJ, Lele KM, Jobanputra V, Salazar G. The A-type cyclins and the meiotic cell cycle in mammalian male germ cells. Int J Androl. 2004;27:192–199
  16. Wolgemuth DJ, Chung SS. Retinoid signaling during spermatogenesis as revealed by genetic and metabolic manipulations of retinoic acid receptor alpha. Soc Reprod Fertil Suppl. 2007;63:11–23
  17. Hild SA, Marshall GR, Attardi BJ, et al. Development of l-CDB-4022 as a nonsteroidal male oral contraceptive: induction and recovery from severe oligospermia in the adult male cynomolgus monkey (Macaca fascicularis). Endocrinology. 2007;148:1784–1796
  18. Mruk DD, Wong CH, Silvestrini B, Cheng CY. A male contraceptive targeting germ cell adhesion. Nat Med. 2006;12:1323–1328
  19. Tash JS, Attardi B, Hild SA, Chakrasali R, Jakkaraj SR, Georg GI. A novel potent indazole carboxylic acid derivative blocks spermatogenesis and is contraceptive in rats after a single oral dose. Biol Reprod. 2008;78:1127–1138
  20. Wong CH, Mruk DD, Lee WM, Cheng CY. Targeted and reversible disruption of the blood–testis barrier by an FSH mutant–occludin peptide conjugate. FASEB J. 2007;21:438–448
  21. Qi H, Moran MM, Navarro B. All four CatSper ion channel proteins are required for male fertility and sperm cell hyperactivated motility. Proc Natl Acad Sci U S A. 2007;104:1219–1223
  22. Navarro B, Kirichok Y, Clapham DE. KSper, a pH-sensitive K+ current that controls sperm membrane potential. Proc Natl Acad Sci U S A. 2007;104:7688–7692
  23. Yeung CH, Barfield JP, Cooper TG. Physiological volume regulation by spermatozoa. Mol Cell Endocrinol. 2006;250:98–105
  24. Da Silva N, Silberstein C, Beaulieu V, et al. Postnatal expression of aquaporins in epithelial cells of the rat epididymis. Biol Reprod. 2006;74:427–438
  25. Sanchez G, Nguyen AN, Timmerberg B, Tash JS, Blanco G. The Na,K-ATPase alpha4 isoform from humans has distinct enzymatic properties and is important for sperm motility. Mol Hum Reprod. 2006;12:565–576
  26. Thundathil JC, Anzar M, Buhr MM. Na+/K+ATPase as a signaling molecule during bovine sperm capacitation. Biol Reprod. 2006;75:308–317
  27. Spehr M, Schwane K, Riffell JA, Zimmer RK, Hatt H. Odorant receptors and olfactory-like signaling mechanisms in mammalian sperm. Mol Cell Endocrinol. 2006;250:128–136
  28. Nomura M, Vacquier VD. Proteins associated with soluble adenylyl cyclase in sea urchin sperm flagella. Cell Motil Cytoskeleton. 2006;63:582–590
  29. Quill TA, Wang D, Garbers DL. Insights into sperm cell motility signaling through sNHE and the CatSpers. Mol Cell Endocrinol. 2006;250:84–92
  30. Strünker T, Weyand I, Bönigk W, et al. A K+-selective cGMP-gated ion channel controls chemosensation of sperm. Nat Cell Biol. 2006;8:1149–1154
  31. Darszon A, Treviño CL, Wood C, et al. Ion channels in sperm motility and capacitation. Soc Reprod Fertil Suppl. 2007;65:229–244
  32. de Lamirande E, O'Flaherty C. Sperm activation: role of reactive oxygen species and kinases. Biochim Biophys Acta. 2008;1784:106–115
  33. Krisfalusi M, Miki K, Magyar PL, O'Brien DA. Multiple glycolytic enzymes are tightly bound to the fibrous sheath of mouse spermatozoa. Biol Reprod. 2006;75:270–278
  34. Miki K, Qu W, Goulding EH, et al. Glyceraldehyde 3-phosphate dehydrogenase-S, a sperm-specific glycolytic enzyme, is required for sperm motility and male fertility. Proc Natl Acad Sci USA. 2004;101:16501–16506
  35. Page ST, Amory JK, Anawalt BD, et al. Testosterone gel combined with depomedroxyprogesterone acetate is an effective male hormonal contraceptive regimen and is not enhanced by the addition of a GnRH antagonist. J Clin Endocrinol Metab. 2006;91:4374–4380

 Author Disclosure: Diana Blithe does not report any conflicts of interest with the sponsor of this supplement article or products discussed in this article.

PII: S0010-7824(08)00276-X

doi: 10.1016/j.contraception.2008.03.018

Contraception
Volume 78, Issue 4, Supplement , Pages S23-S27 , October 2008

Article Tools

* Image Usage & Resolution